{"id":562045,"date":"2025-03-07T00:00:00","date_gmt":"2025-03-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0004-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-current-treatment\/"},"modified":"2026-03-31T10:26:47","modified_gmt":"2026-03-31T10:26:47","slug":"cutron0004-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-current-treatment","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0004-2025-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-current-treatment\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia (US)"},"content":{"rendered":"<p>Non-Hodgkin\u2019s lymphoma (<abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>) and chronic lymphocytic leukemia (<abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes. Treatment approaches vary by subtype, but rituximab in combination with chemotherapy remains the mainstay of treatment across <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> subtypes. Recent label expansions are giving hematologist-oncologists an ever-increasing array of treatment options, including Epkinly (Genmab \/ AbbVie) and Brukinsa (BeiGene) for relapsed\/refractory (<abbr title=\"relapsed\/refractory\">R\/R<\/abbr>) follicular lymphoma (<abbr title=\"follicular lymphoma\">FL<\/abbr>) and Breyanzi (Bristol Myers Squibb) for <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>, <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> <abbr title=\"follicular lymphoma\">FL<\/abbr>, and <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> mantle-cell lymphoma (<abbr title=\"mantle cell lymphoma\">MCL<\/abbr>). These advances, alongside shifting prescribing patterns and increasing competition, are reshaping the treatment of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> and <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"BulletListStyle1 BCX8 SCXP268288084 round-bullets\">\n<li>What are the uptake and patient share of key therapies and regimens across all <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> \/ <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> subtypes, according to surveyed hematologist-oncologists?<\/li>\n<li>How does physician prescribing of current treatments vary based on genetic mutations and <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell- and transplant-eligibility criteria?<\/li>\n<li>How do drug-treatment rates vary across key B-cell <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> \/ <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> subtypes by line of therapy?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing patterns in <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> \/ <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr>?<\/li>\n<li>What are the clinical characteristics that physicians consider when prescribing <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies and bispecific antibodies for the various <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> \/ <abbr title=\"chronic lymphocytic leukemia\">CLL<\/abbr> subtypes?<\/li>\n<\/ul>\n<p><b>Primary research: <\/b>Survey of 100 hematologist-oncologists in the United States fielded in December 2024<\/p>\n<p><b>Key drugs covered: <\/b>Breyanzi, Brukinsa, Calquence, Columvi, Epkinly, Imbruvica, Jaypirca, Kymriah, Lunsumio, rituximab, Tecartus, Venclexta, Yescarta<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-562045","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562045\/revisions"}],"predecessor-version":[{"id":562248,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/562045\/revisions\/562248"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=562045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}